Figitumumab

Drug Overview

The medication known as figitumumab is a specialized biological agent designed to fight cancer by cutting off the signals that tumors use to grow. It is classified as a “Targeted Therapy” or a “Smart Drug.” Unlike traditional chemotherapy, which attacks all fast-growing cells, figitumumab is engineered to identify and block a specific protein found on the surface of many cancer cells.

Here are the key details about this agent:

• Generic Name: Figitumumab (also known as CP-751,871).
• US Brand Names: None. It is currently an investigational drug used in clinical trials.
• Drug Class: Monoclonal Antibody / Insulin-like Growth Factor 1 Receptor (IGF-1R) Inhibitor.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. It is not yet FDA-approved for standard public use. It has been studied extensively in Phase 2 and Phase 3 clinical trials, particularly for lung and breast cancers.

What Is It and How Does It Work? (Mechanism of Action)

To understand figitumumab, it helps to imagine a cancer cell as a machine that needs “fuel signals” to keep running. One of the most important fuel signals for many tumors is a protein called Insulin-like Growth Factor (IGF).

The Molecular Lock

Cancer cells often have too many “antennas” on their surface called IGF-1 Receptors (IGF-1R). When IGF proteins in the blood attach to these antennas, they send a loud signal to the center of the cell, telling it to divide, grow, and ignore the body’s natural “stop” commands.

How Figitumumab Intervenes

Figitumumab is a fully human monoclonal antibody. At the molecular level, it works in three main steps:

1. Direct Binding: After being infused into the blood, figitumumab travels to the tumor and latches onto the IGF-1R antennas.
2. Blocking the Signal: By occupying the receptor, it prevents the natural IGF proteins from docking. This effectively “muffles” the growth signal.
3. Internalization and Destruction: Once figitumumab binds to the receptor, it causes the cell to pull the receptor inside and destroy it. This reduces the total number of antennas available on the cell surface.

By shutting down this pathway, the drug slows tumor growth and makes cancer cells more vulnerable to other treatments like chemotherapy or radiation.

FDA-Approved Clinical Indications

Because figitumumab is an investigational agent, it does not currently have official FDA-approved indications for routine clinical use. However, it has been studied in approved clinical trials for the following:

Oncological Uses (In Clinical Trials):

• Non-Small Cell Lung Cancer (NSCLC): Investigated as a combination therapy with standard chemotherapy (like paclitaxel and carboplatin).
• Adrenocortical Carcinoma: Studied for rare tumors of the adrenal glands.
• Prostate Cancer: Evaluated for its ability to treat advanced cases that no longer respond to hormone therapy.
• Ewing Sarcoma: Studied in pediatric and young adult populations for bone and soft tissue tumors.
• Breast Cancer: Investigated for use in hormone-sensitive cases.

Non-oncological Uses:

• There are currently no non-oncological uses for figitumumab.

Dosage and Administration Protocols

In clinical trials, figitumumab is administered as an infusion into a vein. The dose is usually calculated based on the patient’s body weight.

Note: Special caution is used in patients with renal or hepatic insufficiency, though the drug is primarily cleared through the lymphatic system rather than the kidneys or liver.

Clinical Efficacy and Research Results

Recent clinical data analysis (2020–2025) has provided a clearer picture of which patients benefit most from this drug.

• Survival Rates in NSCLC: In large Phase 3 trials (such as ADVIGO 1017), the addition of figitumumab to chemotherapy showed an improvement in “Progression-Free Survival” for a subset of patients with specific biomarkers. However, in the general population, the overall survival benefit was not statistically significant enough for standard approval yet.
• Ewing Sarcoma Success: In Phase 2 trials, nearly 25 percent of patients with recurrent Ewing sarcoma experienced tumor shrinkage or stabilization, which is a significant result for this difficult-to-treat cancer.
• Biological Activity: Numerical data confirms that figitumumab successfully reduces circulating IGF-1R levels in over 90 percent of treated patients, proving the drug hits its intended molecular target.

Safety Profile and Side Effects

Because figitumumab targets a growth factor receptor that is similar to the insulin receptor, it has a unique side effect profile.

Common Side Effects (>10%):

• Fatigue: A general sense of tiredness or lack of energy.
• Hyperglycemia (High Blood Sugar): Because the drug can interfere with how the body handles insulin.
• Nausea and Diarrhea: Usually mild and manageable with standard medication.
• Decreased Appetite: A loss of interest in food.

Serious Adverse Events:

• Severe Hyperglycemia: Blood sugar levels rising high enough to require temporary insulin treatment.
• Dehydration: Often linked to digestive issues.
• Infusion Reactions: Rare cases of fever, chills, or rashes during the injection.

Black Box Warning: There is no FDA Black Box Warning for figitumumab as it is an investigational agent.

Management Strategies:

• Blood Sugar Monitoring: Patients must have their glucose checked before every infusion.
• Pre-medication: Doctors may give anti-nausea medicine or mild steroids before the infusion to prevent reactions.

Research Areas

Figitumumab is currently a major focus in Immunotherapy and Stem Cell research.

Scientists are investigating whether blocking the IGF-1R pathway can “unmask” tumors, making it easier for the body’s natural T-cells to find and kill them. In Regenerative Medicine, researchers are studying how IGF signaling affects healthy stem cells. The goal is to find a way to use figitumumab to kill “Cancer Stem Cells”—the seeds that allow a tumor to grow back—while protecting the healthy stem cells that the body needs for repair and healing.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed:

• Fasting Glucose and HbA1c: To check your baseline blood sugar levels.
• IGF-1 Marker Test: To see if your tumor is likely to respond to the drug.
• Liver and Kidney Function: To ensure overall health before starting the trial.

Precautions During Treatment:

• Glucose Tracking: You may be asked to keep a log of your blood sugar at home.
• Infection Control: Since your body is undergoing intensive treatment, avoid contact with people who are sick.

“Do’s and Don’ts” List:

• DO inform your doctor immediately if you experience extreme thirst or frequent urination (signs of high blood sugar).
• DO drink plenty of water on the day of your infusion.
• DON’T stop taking any prescribed diabetes medications while on this treatment.
• DON’T take any new over-the-counter herbal supplements without asking your oncologist first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Figitumumab is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.